{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:53:27Z","timestamp":1787507607174,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-024-04692-y","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:57:42Z","timestamp":1736384262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The activity of a herbal medicinal product of Phyllanthus niruri and Silybum marianum powdered extracts (Heptex\u00ae) in patients with apparent risk factors for nonalcoholic steatohepatitis: a phase II, multicentered, randomized, double-blind, placebo-controlled clinical trial"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-4793","authenticated-orcid":false,"given":"Mohamed Kamal","family":"Shaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hassany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basem","family":"Eysa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdulMoneim","family":"Adel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Zidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"issue":"6","key":"4692_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.4103\/ijp.IJP_540_20","volume":"53","author":"K Sowjanya","year":"2021","unstructured":"Sowjanya K, Girish C, Bammigatti C, Lakshmi NCP. Efficacy of Phyllanthus niruri on improving liver functions in patients with alcoholic hepatitis: A double-blind randomized controlled trial. Indian J Pharmacol. 2021;53(6):448.","journal-title":"Indian J Pharmacol"},{"issue":"1","key":"4692_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000780","volume":"8","author":"S Tomah","year":"2021","unstructured":"Tomah S, Hamdy O, Abuelmagd MM, Hassan AH, Alkhouri N, Al-Badri MR, Gardner H, Eldib AH, Eid EA. Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt. BMJ Open Gastroenterol. 2021;8(1): e000780.","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"4692_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328\u201357.","journal-title":"Hepatology"},{"issue":"6","key":"4692_CR4","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14478","volume":"40","author":"Y Fouad","year":"2020","unstructured":"Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What\u2019s in a name? Renaming \u2018NAFLD\u2019to \u2018MAFLD.\u2019 Liver Int. 2020;40(6):1254\u201361.","journal-title":"Liver Int"},{"key":"4692_CR5","doi-asserted-by":"crossref","unstructured":"Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T\u00a0et al. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2021; 22(24): 13219.","DOI":"10.3390\/ijms222413219"},{"issue":"1","key":"4692_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"8","key":"4692_CR7","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","volume":"50","author":"G Marchesini","year":"2001","unstructured":"Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844\u201350.","journal-title":"Diabetes"},{"issue":"5","key":"4692_CR8","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1053\/gast.2001.23256","volume":"120","author":"AJ Sanyal","year":"2001","unstructured":"Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120(5):1183\u201392.","journal-title":"Gastroenterology"},{"issue":"1","key":"4692_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.alcohol.2004.07.007","volume":"34","author":"CJ McClain","year":"2004","unstructured":"McClain CJ, Mokshagundam SP, Barve SS, Song Z, Hill DB, Chen T, Deaciuc I. Mechanisms of non-alcoholic steatohepatitis. Alcohol. 2004;34(1):67\u201379.","journal-title":"Alcohol."},{"issue":"3","key":"4692_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40299-016-0282-5","volume":"25","author":"R Maulana","year":"2016","unstructured":"Maulana R, Helms-Lorenz M, Irnidayanti Y, van de Grift W. Autonomous motivation in the Indonesian classroom: Relationship with teacher support through the lens of self-determination theory. The Asia-Pacific Education Res. 2016;25(3):441\u201351.","journal-title":"The Asia-Pacific Education Res."},{"issue":"13","key":"4692_CR11","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.3748\/wjg.v21.i13.3777","volume":"21","author":"Y Takahashi","year":"2015","unstructured":"Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol: WJG. 2015;21(13):3777.","journal-title":"World J Gastroenterol: WJG"},{"issue":"30","key":"4692_CR12","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","volume":"24","author":"S Leoni","year":"2018","unstructured":"Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018;24(30):3361.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"4692_CR13","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","volume":"56","author":"K Tokushige","year":"2021","unstructured":"Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56(11):951\u201363.","journal-title":"J Gastroenterol."},{"issue":"3","key":"4692_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.18433\/J39W2G","volume":"13","author":"SY Pan","year":"2010","unstructured":"Pan SY, Pan S, Yu ZL, Ma DL, Chen SB, Fong WF, Han YF, Ko KM. New perspectives on innovative drug discovery: an overview. J Pharm Pharmaceutical Sci. 2010;13(3):450\u201371.","journal-title":"J Pharm Pharmaceutical Sci."},{"issue":"8","key":"4692_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1586\/17474124.2013.842893","volume":"7","author":"L Abenavoli","year":"2013","unstructured":"Abenavoli L, Bellentani S. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality? Expert Rev Gastroenterol Hepatol. 2013;7(8):677\u20139.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"12","key":"4692_CR16","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.cgh.2017.08.005","volume":"15","author":"KL Hupa","year":"2017","unstructured":"Hupa KL, Jaeckel E, Manns MP. Silymarin for Treatment of Nonalcoholic Steatohepatitis\u2013A New Kid on the Block? Clin Gastroenterol Hepatol. 2017;15(12):1863\u20135.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"4692_CR17","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.freeradbiomed.2012.02.008","volume":"52","author":"C Loguercio","year":"2012","unstructured":"Loguercio C, Andreone P, Brisc C, Cristina Brisc MC, Bugianesi E, Chiaramonte M, Cursaro C, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Rad Biol Med. 2012;52(9):1658\u201365.","journal-title":"Free Rad Biol Med."},{"issue":"6","key":"4692_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jhep.2009.02.023","volume":"50","author":"M Trappoliere","year":"2009","unstructured":"Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 2009;50(6):1102\u201311.","journal-title":"J Hepatol."},{"issue":"8","key":"4692_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1089\/jmf.2015.0104","volume":"19","author":"S Clichici","year":"2016","unstructured":"Clichici S, Olteanu D, Filip A, Nagy A-L, Oros A, Mircea PA. Beneficial effects of silymarin after the discontinuation of CCl4-induced liver fibrosis. J Med Food. 2016;19(8):789\u201397.","journal-title":"J Med Food"},{"issue":"1","key":"4692_CR20","first-page":"9","volume":"5","author":"H Solhi","year":"2014","unstructured":"Solhi H, Ghahremani R, Kazemifar AM, Yazdi ZH. Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial. Caspian J Int Med. 2014;5(1):9.","journal-title":"Caspian J Int Med."},{"key":"4692_CR21","unstructured":"Hashemi SJ, Eskandar H, Sardabi EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. 2009;9(4):265\u201370."},{"key":"4692_CR22","doi-asserted-by":"crossref","unstructured":"Zhong S, Fan Y, Yan Q, Fan X, Wu B, Han Y, Zhang Y, Chen Y, Zhang H and Niu J. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials. Medicine.\u00a02017;96(49):e9061.","DOI":"10.1097\/MD.0000000000009061"},{"issue":"7","key":"4692_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/ptr.1933","volume":"20","author":"R Bhattacharjee","year":"2006","unstructured":"Bhattacharjee R, Sil PC. The protein fraction of Phyllanthus niruri plays a protective role against acetaminophen induced hepatic disorder via its antioxidant properties. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2006;20(7):595\u2013601.","journal-title":"Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives"},{"issue":"2","key":"4692_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pathophys.2006.02.003","volume":"13","author":"M Chatterjee","year":"2006","unstructured":"Chatterjee M, Sarkar K, Sil PC. Herbal (Phyllanthus niruri) protein isolate protects liver from nimesulide induced oxidative stress. Pathophysiology. 2006;13(2):95\u2013102.","journal-title":"Pathophysiology"},{"key":"4692_CR25","doi-asserted-by":"crossref","unstructured":"Venkateswaran PS, Millman I, Blumberg BS. Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies. Proceedings of the National Academy of Sciences. 1987;84(1):274\u20138.","DOI":"10.1073\/pnas.84.1.274"},{"issue":"12","key":"4692_CR26","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1211\/jpp.58.12.0001","volume":"58","author":"G Bagalkotkar","year":"2006","unstructured":"Bagalkotkar G, Sagineedu SR, Saad MS, Stanslas J. Phytochemicals from Phyllanthus niruri Linn. and their pharmacological properties: a review. J Pharm Pharmacol. 2006;58(12):1559\u201370.","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"4692_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.fct.2006.10.029","volume":"45","author":"R Bhattacharjee","year":"2007","unstructured":"Bhattacharjee R, Sil PC. Protein isolate from the herb, Phyllanthus niruri L. (Euphorbiaceae), plays hepatoprotective role against carbon tetrachloride induced liver damage via its antioxidant properties. Food Chem Toxicol. 2007;45(5):817\u201326.","journal-title":"Food Chem Toxicol"},{"key":"4692_CR28","unstructured":"Manjrekar AP, Jisha V, Bag PP, Adhikary B, Pai MM, Hegde A, and Nandini M. Effect of Phyllanthus niruri Linn. treatment on liver, kidney and testes in CCl 4 induced hepatotoxic rats. 2008."},{"issue":"4","key":"4692_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3109\/19390211.2010.522553","volume":"7","author":"IC Obidike","year":"2010","unstructured":"Obidike IC, Salawu OA, Ndukuba M, Okoli CO, Osunkwo UA. The anti-inflammatory and antinociceptive properties of the chloroform fraction from Phyllanthus niruri plant is mediated via the peripheral nervous system. J Diet Supplement. 2010;7(4):341\u201350.","journal-title":"J Diet Supplement."},{"key":"4692_CR30","doi-asserted-by":"crossref","unstructured":"Hassan MR, Mustapha NR, Jaya F, Arjunan S, Ooi ET, Said RM, Menon J. et al. Efficacy and Safety of Phyllanthus Niruri in Non-alcoholic Steatohepatitis Treatment: Pilot Study from Malaysia. J Pharm Pract Commun Med. 2017;3(3):131\u20137.","DOI":"10.5530\/jppcm.2017.3.29"},{"issue":"1","key":"4692_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226185","volume":"15","author":"MI Ezzat","year":"2020","unstructured":"Ezzat MI, Okba MM, Ahmed SH, El-Banna HA, Prince A, Mohamed SO, et al. In-depth hepatoprotective mechanistic study of Phyllanthus niruri: In vitro and in vivo studies and its chemical characterization. PLoS One. 2020;15(1): e0226185.","journal-title":"PLoS ONE"},{"issue":"7","key":"4692_CR32","first-page":"300","volume":"7","author":"EMI Aida","year":"2015","unstructured":"Aida EMI, Ashraf ANB, Alaa B. Potential genotoxicity and histopathological alteration evaluation of Heptex\u00ae. Int J Pharm Pharm Sci. 2015;7(7):300\u20136.","journal-title":"Int J Pharm Pharm Sci"},{"key":"4692_CR33","doi-asserted-by":"crossref","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine. 2010;362(18):1675\u201385.","DOI":"10.1056\/NEJMoa0907929"},{"key":"4692_CR34","unstructured":"Clinical trial to investigate the anti-oxidant activity of Heptex in patients with apparent risk factors of NASH. ClinicalTrials.gov Identifier: NCT05343780 [Internet]. (2022) [cited 2023 May 18]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05343780"},{"issue":"2","key":"4692_CR35","first-page":"1073","volume":"8","author":"X Ni","year":"2016","unstructured":"Ni X, Wang H. Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). American journal of translational research. 2016;8(2):1073.","journal-title":"American journal of translational research"},{"issue":"6","key":"4692_CR36","first-page":"043","volume":"12","author":"S Anuragh","year":"2022","unstructured":"Anuragh S, Ilango K. Role of medicinal plants and their chemical constituents in ameliorating the cause for non-alcoholic fatty liver disorder\u2014A review. Journal of Applied Pharmaceutical Science. 2022;12(6):043\u201355.","journal-title":"Journal of Applied Pharmaceutical Science"},{"issue":"4","key":"4692_CR37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362\u201373.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4692_CR38","doi-asserted-by":"publisher","unstructured":"Woreta TA, Van Natta ML, Lazo M, Krishnan A, Neuschwander-Tetri BA, Loomba R, et al. Validation of the accuracy of the FASTTM score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS One [Internet]. 2022;17(4 April):1\u201317. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0266859","DOI":"10.1371\/journal.pone.0266859"},{"key":"4692_CR39","doi-asserted-by":"crossref","unstructured":"Navarro VJ, Belle SH, D\u2019Amato M, Adfhal N, Brunt EM, Fried MW, K. Reddy R, Wahed AS, Harrison S and Silymarin in NASH and C Hepatitis (SyNCH) Study Group. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. PLoS One. 2019; 14(9): e0221683.","DOI":"10.1371\/journal.pone.0221683"},{"issue":"12","key":"4692_CR40","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","volume":"15","author":"CW Kheong","year":"2017","unstructured":"Kheong CW, Mustapha NR, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017;15(12):1940\u20139.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"4692_CR41","first-page":"761","volume":"46","author":"KR Shaikh","year":"2021","unstructured":"Shaikh KR, Shaikh S, Ata MA, Memon A, Soomro UA, Siddiqui SS. Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease. Rawal Med J. 2021;46(4):761\u2013761.","journal-title":"Rawal Med J."},{"key":"4692_CR42","doi-asserted-by":"crossref","unstructured":"Mirhashemi SH, Hakakzadeh A, Yeganeh FE, Oshidari B, Rezaee SP. Effect of 8 Weeks milk thistle powder (silymarin extract) supplementation on fatty liver disease in patients candidates for bariatric surgery. Metabolism Open. 2022: 100190.","DOI":"10.1016\/j.metop.2022.100190"},{"issue":"2","key":"4692_CR43","first-page":"267","volume":"122","author":"IA Negoita","year":"2018","unstructured":"Negoita IA, Soloman DE, Georgiana RO. The evaluation of hepatoprotective effect of silymarin, Phyllanthus niruri extract and choline combination. Med Surg J. 2018;122(2):267\u201375.","journal-title":"Med Surg J."},{"key":"4692_CR44","doi-asserted-by":"crossref","unstructured":"Fratila OV, Mihele AI, Hodisan-Pap EF, Hocopan SC, Brata R, Ilias TI\u00a0and Ilias\u00a0T. Comparative hepatoprotective efficacy of silymarin-phyllanthus-choline combination versus silymarin alone in liver diseases with different destruction and inflammation stages. Farmacia.\u00a02020;68(2):299\u2013306.","DOI":"10.31925\/farmacia.2020.2.15"},{"issue":"7","key":"4692_CR45","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3390\/nu9070766","volume":"9","author":"RH AlZarzour","year":"2017","unstructured":"AlZarzour RH, Ahmad M, Asmawi MZ, Kaur G, Saeed MA, Al-Mansoub MA, Saghir SA, Usman NS, Al-Dulaimi DW, Yam MF. Phyllanthus niruri standardized extract alleviates the progression of non-alcoholic fatty liver disease and decreases atherosclerotic risk in Sprague-Dawley rats. Nutrients. 2017;9(7):766.","journal-title":"Nutrients."},{"issue":"5","key":"4692_CR46","first-page":"1399","volume":"22","author":"AL Buchman","year":"1995","unstructured":"Buchman AL, Dubin MD, Moukarzel AA, Jenden DJ, Roch M, Rice KM, Gornbein J, Ament ME. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology. 1995;22(5):1399\u2013403.","journal-title":"Hepatology"},{"issue":"7","key":"4692_CR47","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s10620-012-2098-3","volume":"57","author":"P Charatcharoenwitthaya","year":"2012","unstructured":"Charatcharoenwitthaya P, Lindor KD, Angulo P. The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57(7):1925\u201331.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"4692_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5604\/01.3001.0010.7536","volume":"17","author":"S Gitto","year":"2018","unstructured":"Gitto S, Cicero AF, Loggi E, Giovannini M, Conti F, Grandini E, Guarneri V, et al. Worsening of serum lipid profile after direct acting antiviral treatment. Annal Hepatol. 2018;17(1):64.","journal-title":"Annal Hepatol."}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-024-04692-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-024-04692-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-024-04692-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T01:02:30Z","timestamp":1736384550000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-024-04692-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4692"],"URL":"https:\/\/doi.org\/10.1186\/s12906-024-04692-y","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were performed in accordance with relevant international and local guidelines and regulations. The study protocol was approved by the Egyptian Ministry of Health and Population (MoHP) Research Ethics Committee (code: 3-2020\/13), the National Hepatology and Tropical Medicine Research Institute (NHTMRI) Research Ethics Committee (code: ITH00001), and Ain Shams University Research Ethics Committee (code: P02c\/2019-2022). Informed consent was obtained from all participants prior to conducting any study-related procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Shahnaz Mohamed is an employee of Natural Wellness. The rest of the authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}